Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryos, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.
Leading companies operating in the global stem cell therapy market have undertaken various organic and inorganic growth strategies. The global stem cell therapy market comprises MEDIPOST, Pharmicell Co., Inc; RichSource , BioTime, Inc.; Mesoblast Limited, Holostem Terapie Avanzate Srl; U.S. Stem Cell, Inc; Caladrius Biosciences, Inc.; TiGenix NV, AlloSource. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as product launches in the global stem cell therapy market, resulting in the market’s growth. Moreover, the market players have also deployed several inorganic strategies, including mergers & acquisitions and collaborations that helped the Company to strengthen its revenue, which allows the Company to hold a strong position in the market.